Liquid Biopsy for Precision Oncology Summit on February 18-20, 2025 in La Jolla, United States

Over the past 12 months, liquid biopsy testing has continued to revolutionize diagnostics and personalized medicine; from the integration of AI and automation to elevate liquid biopsy capabilities, to the approval of MRD as an endpoint in Multiple Myeloma.

Cementing its position as the world's leading forum for liquid biopsy specialists, the 9th Liquid Biopsy for Precision Oncology Summit returns to San Diego in February - with a refreshed agenda providing crucial insights spanning biomarker discovery to commercialization, and each critical step in between.

Whether you're new to the field or a seasoned expert, join over 250 of the industry's top decision-makers from AstraZeneca, Amgen, Eli Lilly, AbbVie, BLOODPAC, Boundless Bio, and more to ensure you and your team are equipped with the insights and connections needed to effectively integrate liquid biopsies into clinical trials and drive meaningful progress in precision oncology.

URLs:
Tickets: https://go.evvnt.com/2755765-2?pid=10008
Brochure: https://go.evvnt.com/2755765-3?pid=10008

Time: 1:00 PM - 5:00 PM

Prices:

Drug Developer, Academic and Not-for-Profit Pricing - 2 Day Pass (Conference Only): USD 0.50,

Drug Developer, Academic and Not-for-Profit Pricing - 3 Day Pass (Conference + Workshops and Engagers): USD 0.50,

Solution Providers Pricing - 2 Day Pass (Conference Only): USD 3999.00

Speakers: Anneleen Daemen, Executive Director, Translational Medicine and Head of Bioinformatics, ORIC Pharmaceuticals, Anthoula Lazaris, Scientific Director, RI-MUHC Liver Disease Biobank, Chris Conn, Director, Clinical Biomarkers and Diagnostics, Global Diagnostics Strategy Lead, Amgen, Cynthia Sandoval, PhD Senior Director, Clinical Biomarker Development, Eli Lilly, David Weingeist, Scientific Director, Oncology Diagnostics Leader, Johnson and Johnson Innovative Medicine, David Westenberg, Managing Director, Equity Research, Piper Sandler, Deepa Parthasarathy, Director and Head, Biomarker Operations, Repare Therapeutics, Fatima Khaiser, Associate Director, Regulatory Affaris IVD and CDx, Abbvie, Greg Opiteck, Head, Precision and Translational Medicine, Affini-T Therapeutics, Hua Gong, Senior Vice President and Global Head, Translational Medicine and Clinical Biomarker, Zai Lab, Hugh Wang, Director, Bioinformatics, Summit Therapeutics, Jean-Francois Martini, Executive Director, Translational Oncology Lead, Global Product Development, Oncology, Pfizer, Joe McDermott, Bioinformatics Lead, Lantern Pharma, John Baden, Executive Director, Head of Solid Tumour Oncology Diagnostics, Bristol Myers Squibb, Laura Leiman, Executive Director, BLOODPAC, Lisa Boersma, Associate Director, Precision Medicine and Companion Diagnostics, Regeneron, Marielena Mata, Sr. Director, Clinical Biomarkers, Vividion Therapeutics, Michael Stocum, Chief Executive Officer, Bantum Pharmaceuticals, Mini Manchanda, Director, Clinical Biomarkers and Companion Diagnostics, Kura Oncology, Olena Barbash, Vice President, Biomarkers and Translational Research, EMU, GSK, Olivier Harismendy, Vice President, Translational Data Science and Computational Biology, Zentalis Pharmaceuticals, Paul Krzyzanowski, Medical Director, Precision Medicine, Johnson and Johnson Innovative Medicine, Peter Krein, Senior Vice President, Precision Medicine, Boundless Bio, Peter Teriete, Senior Director and Head of Lead Discovery, IDEAYA Biosciences, Qian Shi, Professor of Biostatistics and Oncology, Mayo Clinic, Robert Feeny, Director Account Solutions, Personalized and Precision Medicine, Novartis, Sarah Shagan, Clinical Biomarker Lead, Genentech, Stephen Huang, Executive Director, Clinical Biomarkers and Companion Diagnostics, Avenzo Therapeutics, Valerie Mbella, Global Director, Regulatory Affairs, Johnson and Johnson Innovative Medicine, Veerendra Munugalavadla, Senior Director and Team Lead, Translational Medicine, Hematology R and D, AstraZeneca